Photo of Praful Ravi,  MB, BChir, MRCP

Praful Ravi, MB, BChir, MRCP

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Praful Ravi, MB, BChir, MRCP

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Medical Oncologist, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a Medical Oncologist at the Lank Center for Genitourinary Oncology at Dana-Farber. My primary research interests are in prostate cancer, specifically (1) neoadjuvant therapy in high-risk disease, (2) radiopharmaceutical therapy and imaging, and (3) biomarkers and endpoints in localized disease.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs DS, Ravi P, Hussain SA, Murad MH, Boorjian SA, Sweeney C, Van Allen EM, Bryce AH. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. JAMA Oncol 2023. PubMed
  • Antonelli L, Ardizzone D, Ravi P, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Fizazi K, King JM, Adra N, Douglawi A, Cary C, Sweeney C, Fankhauser CD. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospectiv Eur J Cancer 2023; 182:144-154. PubMed
  • Ravi P, Whelpley B, Kelly E, Wolanski A, Ritzer J, Robertson M, Shah H, Morgans AK, Wei XX, Sunkara R, Pomerantz M, Taplin ME, Kilbridge KL, Choudhury AD, Jacene H. Clinical Implementation of Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges. J Nucl Med 2023. PubMed
  • Ravi P, Choudhury AD. Defining Patient Benefits from High-intensity Intermittent Therapy for Hormone-sensitive Prostate Cancer. Eur Urol Focus 2023. PubMed
  • Braga-Basaria M, Travison TG, Taplin ME, Lin A, Dufour AB, Habtemariam D, Nguyen PL, Kibel AS, Ravi P, Bearup R, Kackley H, Kafel H, Reid K, Storer T, Simonson DC, McDonnell M, Basaria S. Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLoS ONE 2023; 18:e0281508. PubMed
  • Riaz IB, Islam M, Ikram W, Naqvi SAA, Maqsood H, Saleem Y, Riaz A, Ravi P, Wang Z, Hussain SA, Warner JL, Odedina FT, Duma N, Singh P, Kehl KL, Kamran SC, Murad MH, Landman A, Van Allen E, Bryce AH. Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. JAMA Oncol 2022. PubMed
  • Shah H, Ravi P, Sonpavde G, Jacene H. Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther 2022; 22:1163-1175. PubMed
  • Ravi P, Kwak L, Xie W, Kelleher K, Acosta AM, McKay RR, Kibel AS, Taplin ME. Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis. J Urol 2022; 208:838-845. PubMed
  • Vicier C, Ravi P, Kwak L, Werner L, Huang Y, Evan C, Loda M, Hamid AA, Sweeney CJ. Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer. Prostate 2020. PubMed